BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 30887583)

  • 1. Addressing the room for improvement in management of acute promyelocytic leukemia.
    Nørgaard JM; Friis LS; Kristensen JS; Severinsen MT; Mølle I; Marcher CW; Møller P; Schoellkopf C; Nielsen OJ; Preiss BS; Andersen MK; Kjeldsen E; Medeiros BC; Østgård LSG;
    Eur J Haematol; 2019 Jun; 102(6):479-485. PubMed ID: 30887583
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry.
    Lehmann S; Ravn A; Carlsson L; Antunovic P; Deneberg S; Möllgård L; Derolf AR; Stockelberg D; Tidefelt U; Wahlin A; Wennström L; Höglund M; Juliusson G
    Leukemia; 2011 Jul; 25(7):1128-34. PubMed ID: 21502956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The global problem of early deaths in acute promyelocytic leukemia: A strategy to decrease induction mortality in the most curable leukemia.
    Jillella AP; Kota VK
    Blood Rev; 2018 Mar; 32(2):89-95. PubMed ID: 29033137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia.
    Kim MJ; Yoon HS; Cho SY; Lee HJ; Suh JT; Lee J; Yoon HJ; Lee WI; Park TS
    Cancer Genet Cytogenet; 2010 Sep; 201(2):116-21. PubMed ID: 20682396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethnic differences in acute promyelocytic leukaemia between New Zealand Polynesian and European patients.
    Varghese C; Liu VY; Immanuel T; Chien N; Green T; Chan G; Theakston E; Kalev-Zylinska M
    Hematology; 2021 Dec; 26(1):215-224. PubMed ID: 33594940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABO identical and washed blood transfusions as candidate strategies to reduce early mortality in acute promyelocytic leukemia.
    Sahai T; Henrichs K; Refaai M; Heal JM; Kirkley SA; Schmidt AE; Mendler JH; Masel D; Liesveld J; Aquina C; Blumberg N
    Leuk Res; 2017 Nov; 62():1-3. PubMed ID: 28963906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics and outcome of childhood acute promyelocitic leukemia (APL) in Saudi Arabia: a multicenter SAPHOS leukemia group study.
    Jastaniah W; Alsultan A; Al Daama S; Ballourah W; Bayoumy M; Al-Anzi F; Al Shareef O; Abrar MB; Al Sudairy R; Al Ghemlas I
    Hematology; 2018 Jul; 23(6):316-323. PubMed ID: 29212418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
    Gao N; Wang XX; Sun JR; Yu WZ; Li XZ
    Ann Hematol; 2017 May; 96(5):711-718. PubMed ID: 28238096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel flow cytometric method for enhancing acute promyelocytic leukemia screening by multidimensional dot-plots.
    Kárai B; Habók M; Reményi G; Rejtő L; Ujfalusi A; Kappelmayer J; Hevessy Z
    Ann Hematol; 2019 Jun; 98(6):1413-1420. PubMed ID: 30830246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of empirical treatment for newly diagnosed acute promyelocytic leukemia combined with disseminated intravascular coagulation].
    Yang H; Zhu CY; Wang QS; Niu JH; Zhang Q; Zhu HY; Yao ZL; Xu YY; Jing Y; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):315-22. PubMed ID: 24762998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens.
    Hecht A; Doll S; Altmann H; Nowak D; Lengfelder E; Röllig C; Ehninger G; Spiekermann K; Hiddemann W; Weiß C; Hofmann WK; Nolte F; Platzbecker U
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):889-896.e5. PubMed ID: 28923666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of an open-label, multicenter, post-marketing surveillance study cohort.
    Matsushita T; Watanabe J; Honda G; Mimuro J; Takahashi H; Tsuji H; Eguchi Y; Kitajima I; Sakata Y
    Thromb Res; 2014 May; 133(5):772-81. PubMed ID: 24636871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Promyelocytic Leukemia in Children: A Model of Precision Medicine and Chemotherapy-Free Therapy.
    Gurnari C; Voso MT; Girardi K; Mastronuzzi A; Strocchio L
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of disseminated intravascular coagulation in acute leukemia reveals markedly elevated D-dimer levels are a sensitive indicator of acute promyelocytic leukemia.
    Shahmarvand N; Oak JS; Cascio MJ; Alcasid M; Goodman E; Medeiros BC; Arber DA; Zehnder JL; Ohgami RS
    Int J Lab Hematol; 2017 Aug; 39(4):375-383. PubMed ID: 28422420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical features and treatment outcomes of six patients with disseminated intravascular coagulation resulting from acute promyelocytic leukemia and treated with recombinant human soluble thrombomodulin at a single institution.
    Kawano N; Kuriyama T; Yoshida S; Yamashita K; Ochiai H; Nakazaki S; Tasaki A; Ueda A
    Intern Med; 2013; 52(1):55-62. PubMed ID: 23291674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged treatment with arsenic trioxide (ATO) and all-trans-retinoic acid (ATRA) for relapsed acute promyelocytic leukemia previously treated with ATRA and chemotherapy.
    Cicconi L; Breccia M; Franceschini L; Latagliata R; Molica M; Divona M; Diverio D; Rizzo M; Ottone T; Iaccarino L; Alfonso V; Foa R; Voso MT; Lo-Coco F
    Ann Hematol; 2018 Oct; 97(10):1797-1802. PubMed ID: 29951912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving acute promyelocytic leukemia (APL) outcome in developing countries through networking, results of the International Consortium on APL.
    Rego EM; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte Mdel R; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Martinez L; Meillón LA; Gómez-Almaguer D; Kwaan HC; Garcés-Eisele J; Gallagher R; Niemeyer CM; Schrier SL; Tallman M; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA
    Blood; 2013 Mar; 121(11):1935-43. PubMed ID: 23319575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
    Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
    J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.